1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Acute coronary syndromes

Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome

Medtech innovation briefing [MIB223] Published: 11 August 2020

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Expert comments
  • Expert commentators
  • Development of this briefing
Download (PDF)

Advice

  • Next

Regulatory information

Regulatory information

Spartan RX is CE marked as a class I in vitro diagnostic.


  • Next